Azd-2281 Lynparza (Olaparib) CAS 763113-22-0 to Treat Advanced Ovarian Cancer

Product Description

Product Description  
laparib (AZD2281, Ku-0059436)
AZD2281 Ku-0059436
Olaparib (AZD2281, Ku-0059436) is a selective PARP1 / 2 inhibitor with an IC50 of 5 nM / 1 nM in cell-free assays, 300-fold stronger than that of Tankyrase-1. Phase 3
Chemical Name : 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
CAS :763113-22-0
MF:    C24H23FN4O3
MW:    434.46
Solubility (25°C) : DMSO 86 mg/mL warming (197.94 mM) Water 0.002 mg/mL (0.0 mM) Ethanol <1 mg/mL
Stability :-20ºC Powder , 3 years : -80ºC Soluble in solvents 2years
Usage:Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.


Application
Ovarian cancer forms in the ovary, one of a pair of female reproductive glands where ova, or eggs, are formed.
Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor that blocks enzymes involved in repairing damaged DNA. It is intended for women with heavily pretreated ovarian cancer that is associated with defective BRCA genes.

"Today's approval constitutes the first of a new class of drugs for treating ovarian cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.

The FDA approved Lynparza with a genetic test called BRACAnalysis CDx, a companion diagnostic that will detect the presence of mutations in the BRCA genes (gBRCAm) in blood samples from patients with ovarian cancer. The BRCA genes are involved with repairing damaged DNA and normally work to suppress tumor growth. Women with mutations resulting in defective BRCA genes are more likely to get ovarian cancer, and it is estimated that 10 to 15 percent of all ovarian cancer is associated with these hereditary BRCA mutations.


Description:

Olapanil is a novel poly-ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediates a mechanism of DNA repair and plays an important role in DNA damage repair and cell apoptosis. Therefore, the mechanism of DNA damage repair by targeting to cells is mediated by PARP1 and PARCA2 mutant cancer cells Of the critical loopholes in the role, can be used for breast cancer susceptibility gene (BRCA) mutations, platinum-sensitive drug-resistant patients with recurrent severe ovarian cancer maintenance therapy.

Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug. 

Scientists from Harvard Medical School Dana - Farber Cancer Institute have found that the target site of olaparib is the polymerase Q (POLQ, also known POLθ). Those scientists found that a large number of patients of ovarian cancer has the genetic deficiency in the homologous recombination (homologous recombination, HR) repair pathway and dramatic up-regulated expression of POLQ greatly. Since HR is an important repair pathway for repairing broken DNA, they speculated that the major function of POLQ is to compensate for the lack of HR and participate in DNA repair.

 

      
More details: 

1.Price: Please let us know the quantity you required, because for small order and bulk purchase, the price will be difference.

2.Payment: Western Union, MoneyGram We will supply the receiver's information or the bank account information for payment use.

3.Shipping items: Shipping items will be delivered by international express like EMS, TNT, UPS, FedEx or DHL after receiving received.

4.Every item will be shipped out in 1-2working days after the payment is done. The product usually arrives in 1-4 days based on the different destination, and online track is provided. Please kindly supply the shipping address, contact and tel number for successful shipment.

5.We are 100% confident of my shipment method, None of our previous packages has ever had any delivery issues.

Product Description

Product Description  
laparib (AZD2281, Ku-0059436)
AZD2281 Ku-0059436
Olaparib (AZD2281, Ku-0059436) is a selective PARP1 / 2 inhibitor with an IC50 of 5 nM / 1 nM in cell-free assays, 300-fold stronger than that of Tankyrase-1. Phase 3
Chemical Name : 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
CAS :763113-22-0
MF:    C24H23FN4O3
MW:    434.46
Solubility (25°C) : DMSO 86 mg/mL warming (197.94 mM) Water 0.002 mg/mL (0.0 mM) Ethanol <1 mg/mL
Stability :-20ºC Powder , 3 years : -80ºC Soluble in solvents 2years
Usage:Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.


Application
Ovarian cancer forms in the ovary, one of a pair of female reproductive glands where ova, or eggs, are formed.
Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor that blocks enzymes involved in repairing damaged DNA. It is intended for women with heavily pretreated ovarian cancer that is associated with defective BRCA genes.

"Today's approval constitutes the first of a new class of drugs for treating ovarian cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.

The FDA approved Lynparza with a genetic test called BRACAnalysis CDx, a companion diagnostic that will detect the presence of mutations in the BRCA genes (gBRCAm) in blood samples from patients with ovarian cancer. The BRCA genes are involved with repairing damaged DNA and normally work to suppress tumor growth. Women with mutations resulting in defective BRCA genes are more likely to get ovarian cancer, and it is estimated that 10 to 15 percent of all ovarian cancer is associated with these hereditary BRCA mutations.


Description:

Olapanil is a novel poly-ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediates a mechanism of DNA repair and plays an important role in DNA damage repair and cell apoptosis. Therefore, the mechanism of DNA damage repair by targeting to cells is mediated by PARP1 and PARCA2 mutant cancer cells Of the critical loopholes in the role, can be used for breast cancer susceptibility gene (BRCA) mutations, platinum-sensitive drug-resistant patients with recurrent severe ovarian cancer maintenance therapy.

Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug. 

Scientists from Harvard Medical School Dana - Farber Cancer Institute have found that the target site of olaparib is the polymerase Q (POLQ, also known POLθ). Those scientists found that a large number of patients of ovarian cancer has the genetic deficiency in the homologous recombination (homologous recombination, HR) repair pathway and dramatic up-regulated expression of POLQ greatly. Since HR is an important repair pathway for repairing broken DNA, they speculated that the major function of POLQ is to compensate for the lack of HR and participate in DNA repair.

 

      
More details: 

1.Price: Please let us know the quantity you required, because for small order and bulk purchase, the price will be difference.

2.Payment: Western Union, MoneyGram We will supply the receiver's information or the bank account information for payment use.

3.Shipping items: Shipping items will be delivered by international express like EMS, TNT, UPS, FedEx or DHL after receiving received.

4.Every item will be shipped out in 1-2working days after the payment is done. The product usually arrives in 1-4 days based on the different destination, and online track is provided. Please kindly supply the shipping address, contact and tel number for successful shipment.

5.We are 100% confident of my shipment method, None of our previous packages has ever had any delivery issues.

Albany Style High Speed Rolling Doors

KENVO DOOR aims to produce high premium quality industrial High Speed Doors for our clients. Our rapid doors are with similar design and function as Albany brand doors, but with a much lower price.

So, KENVO high speed door will have very low maintenance as Albany brand doors, and also save your one-time purchase cost at the beginning.

Albany rapid door, Albany high speed door, Albany fast door

SHANGHAI KENVO DOOR CO.,LTD , https://www.kenvodoor.com